HAIC + tislelizumab + lenvatinib

This is a combination regimen consisting of hepatic arterial infusion chemotherapy (HAIC), the PD-1 inhibitor monoclonal antibody tislelizumab, and the multikinase inhibitor small molecule lenvatinib. HAIC delivers chemotherapeutic agents directly into the hepatic artery to target liver tumors. Tislelizumab is an immune checkpoint inhibitor that blocks programmed cell death protein 1 (PD-1) on T cells to enhance anti-tumor immunity. Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), platelet-derived growth factor receptor alpha (PDGFRα), RET proto-oncogene, and KIT proto-oncogene receptor tyrosine kinase. This triple combination has been investigated primarily for advanced or unresectable hepatocellular carcinoma (HCC), especially in patients with high tumor burden or portal vein tumor thrombosis. Clinical studies have shown improved overall survival and progression-free survival compared to dual regimens or monotherapy[1][2][4][5].

Other names

HAIC plus lenvatinib and tislelizumabHLP regimentriple combination therapy (HAIC, lenvatinib, tislelizumab)